Status:
UNKNOWN
Diagnostic Accuracy of Quantitative Neuropad Test for Diabetic Peripheral Neuropathy
Lead Sponsor:
First Affiliated Hospital of Chongqing Medical University
Conditions:
Diabetic Peripheral Neuropathy
Eligibility:
All Genders
18-80 years
Brief Summary
This study aimed to evaluate the diagnostic vaule of quantitative Neuropad for diabetic peripheral neuropathy
Detailed Description
This is a diagnostic study. Every patient will undertake Neuropad test, inculding the visual and quantitative screening tests. The visual screening test includes whether the Neuropad test paper change...
Eligibility Criteria
Inclusion
- 1\) diagnosed type 2 diabetic patients; 2) age between 18 and 80 years.
Exclusion
- 1\) patients with type 1 diabetes, secondary diabetes, and patients with pre-existing diabetic foot; 2) exclusion of the following clinical conditions: foot skin lesions (scarring, rash, flaking skin, infection, etc. on the skin of the test site), peripheral arterial occlusive disease, long-term heavy smoking, chronic alcohol abuse, thyroid disease, liver insufficiency (more than 3-fold increase in liver enzymes), renal insufficiency (eGFR ≤ 30 mL /min/1.73m2), acute and chronic infections, cervical and lumbar spine diseases, bone and joint system diseases, other neurological diseases, autoimmune diseases, malignant tumors, psychiatric or psychological diseases, taking drugs that affect autonomic function, and combined with other diseases that can cause peripheral neuropathy; 3) those who cannot complete the experiment as required.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT05347420
Start Date
August 1 2020
End Date
August 1 2023
Last Update
April 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400016